Vericel Corporation (NASDAQ:VCEL) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.
Vericel Corporation, f/k/a Aastrom Biosciences,Inc., (the
Company), a Michigan corporation, is filing this amendment to the
Current Report on Form8-K filed by the Company on November22,
2011 to provide information regarding the counterparty to the
project addendum (the NovemberAddendum) to the Companys master
services agreement (the Agreement), made and entered into as of
September23, 2011, by and between the Company and PPD
Development, L.P. (PPD). A copy of the NovemberAddendum that
includes the identity of PPD as the counterparty is attached to
this Form8-K/A as Exhibit10.1.
Item9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
|
Description |
|
10.1* |
Project Addendum to the Master Services Agreement, dated as |
* Application has been made with the Securities and Exchange
Commission to seek confidential treatment of certain provisions.
Omitted material for which confidential treatment has been
requested has been filed separately with the Securities and
Exchange Commission.
About Vericel Corporation (NASDAQ:VCEL)
Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy. Vericel Corporation (NASDAQ:VCEL) Recent Trading Information
Vericel Corporation (NASDAQ:VCEL) closed its last trading session down -0.10 at 3.00 with 1,041,117 shares trading hands.
